FARMSTAR LIMITED
Company number 02262473 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: FARMSTAR LIMITED
1. Financial Health Score: D (Poor – Requires Active Management)
The company is structurally sound in terms of longevity and market position, but its financial vital signs show clear deterioration. High leverage, critically low cash, and a shrinking net asset base signal that the business is under stress. While no immediate crisis is evident, the underlying trends demand corrective action to avoid more serious complications.
2. Key Vital Signs
| Vital Sign | Value (2024) | Interpretation |
|---|---|---|
| Turnover | £35.8M | Declining 12% year-on-year (from £40.8M in 2023). 3-year trend is negative. |
| Net Assets (Equity) | £3.3M | Down 19% from £4.1M in 2023. Erosion suggests either losses or dividend payments exceeding profit. |
| Cash Reserves | £110k | Only 0.3% of turnover and 0.85% of total liabilities. Critically anaemic – a “thin blood” condition. |
| Debt-to-Equity Ratio | 3.9:1 | Very high. Total liabilities of £12.9M dwarf shareholders’ funds. The company is heavily reliant on borrowed capital. |
| Liability-to-Asset Ratio | 95.2% | Almost all assets are financed by debt. Equity cushion is razor-thin. |
3. Diagnosis – “Financially Breathless with Early Signs of Strain”
- Liquidity Emergency: Cash is dangerously low. While the business likely draws on overdraft and stocking finance facilities to bridge gaps, this dependence means any tightening of credit or interest rate rise could trigger a cash flow crisis.
- Leverage Overload: The debt load is heavy for a company of this size. Interest costs are a constant drain, and net assets are being consumed – possibly to service debt or fund dividends.
- Revenue Weakness: Turnover has fallen by roughly 28% from its 2020 peak. In a capital-intensive dealership, volume drops quickly compress margins.
- Profitability Ambiguity: Without a reported profit figure, the decline in net assets suggests the company is either not earning enough to cover its cost of capital or is distributing capital to shareholders. Either way, the “heart” (earnings power) is not pumping strongly enough.
The overall condition is not yet critical – the company is still active, compliant, and has a strong brand – but the lab results show clear stress markers. Immediate intervention is needed to stabilise liquidity and restore profitability.
4. Recommendations – Prescription for Recovery
- Improve Cash Conversion: Tighten debtor collection terms, reduce stock levels (they acknowledge this risk in the strategic report), and negotiate better payment terms with suppliers. Aim to raise cash to at least 5–10% of liabilities.
- Reduce Debt Burden: Use any excess cash flow to pay down the most expensive debt. Consider refinancing part of the stock funding for longer terms to lower interest exposure.
- Boost Profit Margins: Focus on higher-margin service and parts revenue versus low-margin machinery sales. Target a gross margin improvement of 1–2% through pricing discipline and cost control.
- Equity Reinforcement: If possible, retain earnings rather than paying dividends. A rights issue or capital injection from shareholders would strengthen the balance sheet.
- Monitor Covenant Compliance: With high leverage, the company must stay within the terms of its banking facilities. Regular, proactive dialogue with lenders is essential to avoid defaults.
Executive Summary